Nearly all people with systemic lupus erythematosus (SLE) treated with iCell Gene Therapeutics’ dual-target CAR T-cell therapy achieved medication-free disease remission, according to long-term follow-up data from a small Phase 1 trial. Further, kidney function continued to improve among those with lupus nephritis (LN), a common SLE complication…
Discontinuing glucocorticoid therapy after achieving remission did not increase the risk of symptom flare-ups in people with systemic lupus erythematosus (SLE). That’s according to data presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) congress, as announced in a EULAR press release. Data also showed that…
Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms and severity of systemic lupus erythematosus (SLE), a study shows. While IFNs are known to play a role in the disease, increases in IFN levels don ‘t explain many…
A 27-year-old woman with hard-to-treat systemic lupus erythematosus (SLE), the most common type of lupus, became the first patient treated in an early clinical trial evaluating FT819, Fate Therapeutics’ off-the-shelf CAR T-cell therapy candidate. The Phase 1 study (NCT06308978), taking place at the University of Minnesota Medical…
The U.S. Food and Drug Administration (FDA) has cleared a clinical trial to evaluate the safety and preliminary effectiveness of CB-010, Caribou Biosciences’ investigational CAR T-cell therapy, for lupus that affects the kidneys and other organs. The multicenter Phase 1 trial, dubbed GALLOP, should begin by the end…
The U.S. Food and Drug Administration (FDA) has granted permission for Atara Biotherapeutics to test its lupus nephritis treatment candidate ATA3219 in a Phase 1 clinical trial involving lupus patients with this complication, which is marked by kidney damage and inflammation. The first patient is expected to be…
Modified anti-inflammatory T-regulatory immune cells, known as Tregs, were able to suppress autoimmune activity in cells and in a mouse model of lupus nephritis, a common complication of lupus marked by kidney inflammation, a new study reports. These findings support the development of a Treg-based treatment that uses a…
Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus erythematosus (SLE). As such, the trial failed to meet its primary objective, as assessed using the SLE Responder…
Adding Gazyva (obinutuzumab) to standard-of-care therapy for two years reduced the risk of treatment failure, diminished kidney function or death by 60% in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The number of lupus nephritis flares, or periods of sudden worsening, also…
The U.S. Food and Drug Administration (FDA) has approved Nkarta’s request to launch a clinical trial in the U.S. to test its experimental therapy NKX019 in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The multi-center, dose-escalation study will assess the safety and clinical…